Assessment of crispra-mediated gdnf overexpression in an in vitro parkinson’s disease model

HIGHLIGHTS

• What: COPYRIGHT and This is an open-access Article distribution or reproduction in other forums is permitted provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited in accordance with accepted academic practice. The study shows that increasing gdnf expression can remediate some of the cellular symptoms associated with Parkinson`s disease in an in_vitro model of the disease using a novel nanostructured delivery system. To comprehensively evaluate the effects of gdnf overexpression, the authors analyzed cellular responses and the resulting alterations in the in_vitro . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.